All news

Truist lifts Regeneron price target to $780

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Truist Financial raised its price target on Regeneron Pharmaceuticals (NASDAQ:REGN) to $780 from $772, keeping a buy rating. The move follows a broadly positive analyst backdrop, with JPMorgan and Guggenheim also lifting targets recently. Regeneron beat earnings expectations for its latest quarter, reporting EPS of

Read original source

REGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.